These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

466 related items for PubMed ID: 12163626

  • 21. (18)F-FDG PET and conventional imaging for assessment of Hodgkin's disease and non Hodgkin's lymphoma. An analysis of 193 patient studies.
    Bucerius J, Herkel C, Joe AY, Altehoefer C, Finke J, Moser E, Reinhardt MJ.
    Nuklearmedizin; 2006; 45(3):105-10; quiz N25-6. PubMed ID: 16710505
    [Abstract] [Full Text] [Related]

  • 22. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.
    Kostakoglu L, Leonard JP, Kuji I, Coleman M, Vallabhajosula S, Goldsmith SJ.
    Cancer; 2002 Feb 15; 94(4):879-88. PubMed ID: 11920454
    [Abstract] [Full Text] [Related]

  • 23. Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma.
    Lee H, Kim SK, Kim YI, Kim TS, Kang SH, Park WS, Yun T, Eom HS.
    J Nucl Med; 2014 Feb 15; 55(2):216-22. PubMed ID: 24365650
    [Abstract] [Full Text] [Related]

  • 24. In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma.
    Hutchings M, Kostakoglu L, Zaucha JM, Malkowski B, Biggi A, Danielewicz I, Loft A, Specht L, Lamonica D, Czuczman MS, Nanni C, Zinzani PL, Diehl L, Stern R, Coleman M.
    J Clin Oncol; 2014 Sep 01; 32(25):2705-11. PubMed ID: 25071108
    [Abstract] [Full Text] [Related]

  • 25. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?
    Spaepen K, Stroobants S, Dupont P, Thomas J, Vandenberghe P, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G.
    Br J Haematol; 2001 Nov 01; 115(2):272-8. PubMed ID: 11703321
    [Abstract] [Full Text] [Related]

  • 26. Assessment of Lymphoma Therapy Using (18)F-FDG PET.
    Lowe VJ, Wiseman GA.
    J Nucl Med; 2002 Aug 01; 43(8):1028-30. PubMed ID: 12163627
    [No Abstract] [Full Text] [Related]

  • 27. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation.
    Svoboda J, Andreadis C, Elstrom R, Chong EA, Downs LH, Berkowitz A, Luger SM, Porter DL, Nasta S, Tsai D, Loren AW, Siegel DL, Glatstein E, Alavi A, Stadtmauer EA, Schuster SJ.
    Bone Marrow Transplant; 2006 Aug 01; 38(3):211-6. PubMed ID: 16770314
    [Abstract] [Full Text] [Related]

  • 28. Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease.
    Spaepen K, Mortelmans L.
    Q J Nucl Med; 2001 Sep 01; 45(3):269-73. PubMed ID: 11788819
    [Abstract] [Full Text] [Related]

  • 29. The impact of FDG positron emission tomography imaging on the management of lymphomas.
    Shah N, Hoskin P, McMillan A, Gibson P, Lowe J, wong WL.
    Br J Radiol; 2000 May 01; 73(869):482-7. PubMed ID: 10884743
    [Abstract] [Full Text] [Related]

  • 30. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow.
    Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN.
    J Clin Oncol; 1998 Feb 01; 16(2):603-9. PubMed ID: 9469348
    [Abstract] [Full Text] [Related]

  • 31. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
    Kumar R, Xiu Y, Potenta S, Mavi A, Zhuang H, Yu JQ, Dhurairaj T, Dadparvar S, Alavi A.
    J Nucl Med; 2004 Nov 01; 45(11):1796-803. PubMed ID: 15534046
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
    Shen YY, Kao A, Yen RF.
    Oncol Rep; 2002 Nov 01; 9(2):321-5. PubMed ID: 11836600
    [Abstract] [Full Text] [Related]

  • 34. (18)F-FDG PET in Pediatric Lymphomas: A Comparison with Conventional Imaging.
    Lopci E, Burnelli R, Ambrosini V, Nanni C, Castellucci P, Biassoni L, Rubello D, Fanti S.
    Cancer Biother Radiopharm; 2008 Dec 01; 23(6):681-90. PubMed ID: 19111053
    [Abstract] [Full Text] [Related]

  • 35. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management.
    Montravers F, McNamara D, Landman-Parker J, Grahek D, Kerrou K, Younsi N, Wioland M, Leverger G, Talbot JN.
    Eur J Nucl Med Mol Imaging; 2002 Sep 01; 29(9):1155-65. PubMed ID: 12192560
    [Abstract] [Full Text] [Related]

  • 36. [Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker].
    Pfannenberg AC, Oechsle K, Kollmannsberger C, Dohmen BM, Bokemeyer C, Bares R, Vontheim R, Claussen CD.
    Rofo; 2004 Jan 01; 176(1):76-84. PubMed ID: 14712410
    [Abstract] [Full Text] [Related]

  • 37. Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease.
    Advani R, Maeda L, Lavori P, Quon A, Hoppe R, Breslin S, Rosenberg SA, Horning SJ.
    J Clin Oncol; 2007 Sep 01; 25(25):3902-7. PubMed ID: 17664458
    [Abstract] [Full Text] [Related]

  • 38. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.
    Juweid ME, Wiseman GA, Vose JM, Ritchie JM, Menda Y, Wooldridge JE, Mottaghy FM, Rohren EM, Blumstein NM, Stolpen A, Link BK, Reske SN, Graham MM, Cheson BD.
    J Clin Oncol; 2005 Jul 20; 23(21):4652-61. PubMed ID: 15837965
    [Abstract] [Full Text] [Related]

  • 39. 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT.
    Mikhaeel NG, Timothy AR, O'Doherty MJ, Hain S, Maisey MN.
    Leuk Lymphoma; 2000 Nov 20; 39(5-6):543-53. PubMed ID: 11342337
    [Abstract] [Full Text] [Related]

  • 40. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes.
    Mosavi F, Wassberg C, Selling J, Molin D, Ahlström H.
    Clin Radiol; 2015 Nov 20; 70(11):1229-36. PubMed ID: 26208992
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.